ESC 365 - Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial

ESC Premium Access

Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial

Session: Sleep Disordered Breathing and Cardiovascular Disease: from Evidence to Experience

Topic: Sleep Apnoea

Speaker: Associate Professor H. Yaggi (New Haven, US)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Associate Professor Henry Klar Yaggi

New Haven (United States of America)

0 follower

1 more presentation in this session

Sleep disordered breathing: prevalence and association with cardiovascular disease in the French general population

Speaker: Doctor P. Balagny (Paris, FR)

Access the full session

Sleep Disordered Breathing and Cardiovascular Disease: from Evidence to Experience

Speakers: Associate Professor H. Yaggi, Doctor P. Balagny

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources